Your browser doesn't support javascript.
loading
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction.
Matyas, Csaba; Trojnar, Eszter; Zhao, Suxian; Arif, Muhammad; Mukhopadhyay, Partha; Kovacs, Attila; Fabian, Alexandra; Tokodi, Marton; Bagyura, Zsolt; Merkely, Bela; Kohidai, Laszlo; Lajko, Eszter; Takacs, Angela; He, Yong; Gao, Bin; Paloczi, Janos; Lohoff, Falk W; Haskó, György; Ding, Wen-Xing; Pacher, Pal.
  • Matyas C; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Trojnar E; Department of Medical Imaging, Medical School, University of Pécs, Pécs, Hungary.
  • Zhao S; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Arif M; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Mukhopadhyay P; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Kovacs A; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Fabian A; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Tokodi M; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Bagyura Z; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Merkely B; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Kohidai L; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Lajko E; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
  • Takacs A; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
  • He Y; Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary.
  • Gao B; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Paloczi J; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Lohoff FW; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Haskó G; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
  • Ding WX; Department of Anesthesiology, Columbia University, New York, New York, USA.
  • Pacher P; Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
JACC Basic Transl Sci ; 8(10): 1334-1353, 2023 Oct.
Article en En | MEDLINE | ID: mdl-38094682
ABSTRACT
Cardiovascular diseases (CVDs) are the leading cause of death among elderly people. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of cholesterol metabolism. Herein, we investigated the role of PCSK9 in age-related CVD. Both in humans and rats, blood PCSK9 level correlated positively with increasing age and the development of cardiovascular dysfunction. Age-related fatty degeneration of liver tissue positively correlated with serum PCSK9 levels in the rat model, while development of age-related nonalcoholic fatty liver disease correlated with cardiovascular functional impairment. Network analysis identified PCSK9 as an important factor in age-associated lipid alterations and it correlated positively with intima-media thickness, a clinical parameter of CVD risk. PCSK9 inhibition with alirocumab effectively reduced the CVD progression in aging rats, suggesting that PCSK9 plays an important role in cardiovascular aging.
Palabras clave